Company news

Share this article:
Mylan Pharmaceuticals has entered into a deal with Novartis to market letrozole 2.5 mg tablets, a generic version of Novartis's breast cancer product Femara. Letrozole tablets posted U.S. sales of approximately $470 million for the 12 month period ending Sept. 30, 2008, according to a Mylan statement. 
 
Titan Pharmaceuticals, a manufacturer focused primarily on the development and commercialization of Probuphine, a treatment for opiate addiction, has reduced its workforce by 40%. Further staff reductions are anticipated in the next several weeks, a company statement said. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions